Close
Clinical Trials
A Phase Ia/Ib, 2-Part, Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients with Advanced or Metastatic Solid Tumors
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
John Sarantopoulos MD
For more information about this study
View DetailsAbout This Study
This is a phase Ia/Ib, open-label, dose-escalation and dose-expansion study designed to evaluate BSI-082 monotherapy and combined therapy with Trastuzumab deruxtecan (T-DXd) in patients with locally advanced or metastatic solid tumors.